Crinetics Pharmaceuticals, Inc. (CRNX) News
Filter CRNX News Items
CRNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRNX News Highlights
- CRNX's 30 day story count now stands at 3.
- Over the past 12 days, the trend for CRNX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, MED and RARE are the most mentioned tickers in articles about CRNX.
Latest CRNX News From Around the Web
Below are the latest news stories about CRINETICS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRNX as an investment opportunity.
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ...On December 21, 2023, Chief Med and Dev Officer Dana Pizzuti sold 9,583 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), as indicated by an SEC Filing. |
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid SyndromeSignificant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is Complete (N=36), and Topline Results Expected in 1H 2024 Management to Host a Conference Call Today at 5:00 p.m. Eastern Time SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial f |
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on December 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-execu |
12 Stocks Billionaire Steve Cohen Just Bought and SoldIn this article, we’re going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought and Sold. Billionaire Steve Cohen is one of the most […] |
Crinetics Pharmaceuticals to Participate in Upcoming Investor ConferencesSAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City. Details of the fireside chats are as follows: 6th Annual Evercore ISI HealthCONx Conference:Date: Tuesday, November 28, 2023Time: 3:50 p.m. Eastern Time Piper Sandler 35th Annual Healthcar |
Billionaire Steve Cohen Goes Big on These 2 ‘Strong Buy’ Stocks — Here’s Why You Should FollowThe prospect of a looming recession has been in the background for a while now. Financial prognosticators have generally agreed that one will hit eventually, although its timing and magnitude remain open to debate. But for those concerned about a recession’s impact on the economy and the markets, one legendary Wall Street name has a reassuring take on the matter. Billionaire Steve Cohen, who runs hedge fund Point72 Asset Management, a firm with $31.4 billion of assets under management, expects a |
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on November 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new non-exec |
Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial GrowthKey Developments and Financial Performance for Third Quarter 2023 |
Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High?The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 56.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year. |